Guidelines for the management of paediatric cholera infection: a systematic review of the evidence

References

• Lutz M, Noorian P, Sun S, et al. Environmental reservoirs and mechanisms of persistence of Vibrio cholerae. Front Microbiol. 2013;4:1–15. DOI:10.3389/fmicb.2013.00375
   PubMed Web of Science ®Google Scholar
• Harris JB, LaRocque RC, Charles R, et al. Cholera’s western front. Lancet. 2010;376:1961–1965.
   PubMed Web of Science ®Google Scholar
• Harris R, Qadri F, Ryan E, et al. Cholera. Lancet. 2012;379:466–476.
   Web of Science ®Google Scholar
• Viswanathan VK, Hecht G, Hodges K. Enteric infection meets intestinal function: how bacterial pathogens cause diarrhoea. Nat Rev Microbiol. 2009;7:110–119.
   PubMed Web of Science ®Google Scholar
• Ali A, You Y, Kim Y, et al. The global burden of cholera. Bull WHO. 2012;90(3):157–244.
   Web of Science ®Google Scholar
• Das A, Salam R, Bhutta Z, et al. Antibiotics for the treatment of cholera, shigella and cryptosporidium in children. BMC Public Health. 2013;Suppl. 3:S3–S10.
   PubMedGoogle Scholar
• Deen JL, von Seidlein L, Sur D, et al. The high burden of cholera in children: Comparison of incidence from endemic areas in Asia and Africa. PLoS Negl Trop Dis. 2008;2:e173.
   PubMed Web of Science ®Google Scholar
• Koelle K, Rodó X, Pascual M, et al. Refractory periods and climate forcing in cholera dynamics. Nature. 2005;436:696–700.
   PubMed Web of Science ®Google Scholar
• American Academy of Pediatrics. Vibrio cholera. In: Kimberlin M, Jackson M, Long S, et al., editors. Red Book, 2015. Report of the committee on infectious diseases. 30th ed. Elk Grove Village (IL): American Academy of Pediatrics; 2015. P. 850–853.
   Google Scholar
• Merrell DS, Butler SM, Qadri F, et al. Host-induced epidemic spread of the cholera bacterium. Nature. 2002;417:642–645.
   PubMed Web of Science ®Google Scholar
• Griffith DC, Miller MA, Kelly-Hope LA. Review of reported cholera outbreaks worldwide, 1995–2005. Am J Trop Med Hyg. 2006;75:973–977.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Pocket book of hospital care for children: guidelines for the management of common illnesses with limited. Resources. 2013. Available from: http://apps.who.int/iris/bitstream/10665/43206/1/9241546700.pdf
   Google Scholar
• World Health Organization. The treatment of diarrhoea: a manual for physicians and other senior health workers. 4th revision. Available from: http://apps.who.int/iris/bitstream/10665/43209/1/9241593180.pdf
   Google Scholar
• Khan WA, Saha D, Rahman A, et al. Comparison of single-dose azithromycin and 12-dose, 3-day erythromycin for childhood cholera: a randomised, double-blind trial. Lancet. 2002;360:1722–1727.
   PubMed Web of Science ®Google Scholar
• Nelson EJ. Antibiotics for both moderate and severe cholera. N Engl J Med. 2010;364:5–7.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Recommendations for the use of antibiotics for the treatment of cholera. 2015. Available from: http://www.cdc.gov/cholera/treatment/antibiotic-treatment.html
   Google Scholar
• Greenough WB, Rosenberg IS, Gordon RS, et al. Tetracycline in the treatment of cholera. Lancet. 1964;283:355–357.
   Google Scholar
• Lindenbaum J, Greenhough WB, Islam MR. Antibiotic therapy of cholera. Bull WHO. 1967;36:871–883.
   PubMed Web of Science ®Google Scholar
• Kaushik JS, Gupta P, Faridi MMA, et al. Single dose azithromycin versus ciprofloxacin for cholera in children: a randomized controlled trial. Indian Pediatr. 2010;47:309–315.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Pocket book of hospital care for children: guidelines for the management of common illnesses with limited. Resources. 2005. Available from: http://www.who.int/maternal_child_adolescent/documents/9241546700/en/
   Google Scholar
• Balshem H, Helfand M, Schünemann HJ, et al. Grade guidelines 3: rating the quality of the evidence – introduction. J Clin Epidemiol. 2011;64:401–406.
   PubMed Web of Science ®Google Scholar
• Guerrant RL, Van Gilder T, Steiner TS, et al. Practice guidelines for the management of infectious diarrhea. Clin Infect Dis. 2001;32:331–351.
   PubMed Web of Science ®Google Scholar
• Siddique AK, Nasim SMA. Guidelines for operating makeshift treatment centres in cholera epidemics. ICDDR, B Cent Popul Heal Res. 1997. Available from: http://dspace.icddrb.org/jspui/bitstream/123456789/4021/1/ICDDRBSpecialPub-61.pdf
   Google Scholar
• World Gastroenterology Guidelines. Acute diarrhoea in adults and children. 2012. Available from: http://www.worldgastroenterology.org/guidelines/global-guidelines/acute-diarrhea/acute-diarrhea-english
   Google Scholar
• Green M, Sack D, Alam N, et al. Cholera. Br Med J Best Practice. 2017. Available from: http://bestpractice.bmj.com/best-practice/monograph/451.html
   Google Scholar
• Cholera. eTG complete [Internet]. Melbourne: Therapeutic Guidelines Limited; [revised November 2014], 2015.
   Google Scholar
• Chattaway A, Fashae K, Okoro C, et al. Fluoroquinolone-resistant enteric bacteria in sub-Saharan Africa: clones, implications and research needs. J Front Microbiol. 2016;7:1–20. DOI:10.3389/fmicb.2016.00558.
   Google Scholar
• Mahapatra T, Mahapatra S, Babu GR, et al. Cholera outbreaks in South and South-East Asia: descriptive analysis, 2003–2012. Jpn J Infect Dis. 2014;67:145–156.
   PubMed Web of Science ®Google Scholar
• Saha D, Karim M, Khan W, et al. Single-Dose azithromycin for the treatment of cholera in adults. N Engl J Med. 2006;354:2452–2462.
   PubMed Web of Science ®Google Scholar
• Khan W, Saha D, Ahmed S, et al. Efficacy of ciprofloxacin for treatment of cholera associated with diminished susceptibility of ciprofloxacin to Vibrio cholerae 01. PLoS One. 2015;10:e0134921.
   PubMed Web of Science ®Google Scholar
• Bhattaharya S, Ramamurthy T, Rajendran K, et al. Comparison between single-dose azithromycin and six dose, 3-day norfloxacin for treatment of cholera in adults. Int J Biomed Sci. 2014;10:248–251.
   PubMedGoogle Scholar
• Leibovici-Weissman Y, Neuberger A, Bitterman R, et al. Antimicrobial drugs for treating cholera. Cochrane Database Syst Rev. 2014; 6:1–182. CD0086.
   Google Scholar
• Wasif A, Khan AR, Salam MA, et al. Comparison of single-dose azithromycin and 12-dose, 3-day erythromycin for childhood cholera: a randomised, double-blind trial. Lancet. 2002;360:1722–1727.
   PubMed Web of Science ®Google Scholar
• Saha D, Karim MM, Chowdhury HR, et al. Single-dose ciprofloxacin versus 12-dose erythromycin for childhood cholera: a randomised controlled trial. Lancet. 2005;366:1985–1993.
   PubMed Web of Science ®Google Scholar
• National Committee for Clinical Laboratory Standards. Approved standards M2-A6 performance standards for antimicrobial disk susceptibility tests. 6th ed.; 1997. Available from: https://clsi.org/media/1631/m02a12_sample.pdf
   Google Scholar
• Gitanjali B. Essential medicines for children: should we focus on a priority list of medicines for the present? J Pharmacol Pharmacother. 2011;2:1–2.
   PubMedGoogle Scholar
• Kabir W, Haider R, Mitra A, et al. Erythromycin and trimethoprim-sulphamethoxazole in the treatment of cholera in children. J Diarrhoeal Dis Res. 1996;14:243–247.
   PubMedGoogle Scholar
• Burans J, Podgore J, Mansour MM, et al. Comparative trial of erythromycin and sulphatrimethoprim in the treatment of tetracycline-resistant Vibrio cholerae 01. Trans R Soc Trop Med Hyg. 1989;83:836–838.
   PubMed Web of Science ®Google Scholar
• Khan WA, Bennish ML, Seas C, et al. Randomised controlled comparison of single-dose ciprofloxacin and doxycycline for cholera caused by Vibrio cholerae 01 or 0139. Lancet. 1996;348:296–300.
   PubMed Web of Science ®Google Scholar
• Shentag JJ. Tissue directed pharmacokinetics. Am J Med. 1991;91:40–45.
   Web of Science ®Google Scholar
• Das SK, Klontz EH, Azmi IJ, et al. Characteristics of multidrug resistant shigella and Vibrio cholerae 01 infections in patients treated at an urban and a rural hospital in Bangladesh. ISRN Microbiol. 2013; 2013:8. Article ID 213915. DOI:10.1155/2013/213915
   Google Scholar
• Hancox M, Vieweg V, Crouse E, et al. Azithromycin, cardiovascular risks, QTc interval prolongation, torsade de pointes, and regulatory issues: a narrative review based on the study of case reports. Ther Adv Infec Dis. 2013;1:155–165.
   PubMedGoogle Scholar
• Owens RC, Nolin TD. Antimicrobial-associated QT interval prolongation: pointes of interest. Clin Infect Dis. 2006;43:1603–1611.
   PubMed Web of Science ®Google Scholar
• Dresser GK, Spence JD, Bailey DG. Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition. Clin Pharmacokinet. 2000;38:41–57.
   PubMed Web of Science ®Google Scholar
• Samarendra P, Kumari S, Evans SJ, et al. QT prolongation associated with azithromycin/amiodarone combination. Clin Electrophysiol. 2001;24:1572–1574.
   PubMed Web of Science ®Google Scholar
• Ray W, Murray K, Hall K, et al. Azithromycin and the risk of cardiovascular death. N Engl J Med. 2012;366:1881–1890.
   PubMed Web of Science ®Google Scholar
• Howard P. Azithromycin-induced proarrhythmia and cardiovascular death. Ann Pharmacol. 2013;47:1547–1551.
   Google Scholar
• Chomvarin C, Johura FT, Mannan SB, et al. Drug response and genetic properties of Vibrio cholerae assocated with endemic cholera in north-east Thailand, 2003–2011. J Med Microbiol. 2013;62:599–609.
   PubMed Web of Science ®Google Scholar
• Tran HD, Alam M, Trung N, et al. Multi-drug resistant Vibrio cholerae 01 variant El Tor isolated in northern Vietnam between 2007 and 2010. J Med Microbiol. 2012;61:431–437.
   PubMed Web of Science ®Google Scholar
• Rashed S, Mannan S, Joshura F, et al. Genetic characteristics of drug-resistant Vibrio cholerae 01 causing endemic cholera in Dhaka, 2006–2011. J Med Microbiol. 2012;44:4211–4213.
   Google Scholar
• Mandomando I, Espasa M, Vallès X, et al. Antimicrobial resistance of Vibrio cholerae 01 serotype Ogawa isolated in Manhiça District Hospital, southern Mozambique. J Antimicrob Chemother. 2007;60:662–664.
   PubMed Web of Science ®Google Scholar
• Reveiz L, Chapman E, Ramon-Pardo P, et al. Chemoprophylaxis in contacts of patients with cholera: systematic review and meta-analysis. PLoS ONE. 2011;6:e27060.
   PubMed Web of Science ®Google Scholar
• Christopher P, David K, John S, et al. Antibiotic therapy for Shigella dysentery. Cochrane Database Syst Rev. 2010;8. DOI:10.1002/14651858.CD006784.pub4
   Google Scholar
• British National Formulary for Children. BMJ Publishing Group; 2016. Available from: https://www.medicinescomplete.com.acs.hcn.com.au/about/publications.htm
   Google Scholar